41 reports

  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

ANNOUNCED THAT ANTI-INFLUENZA DRUG CANDIDATES UNDER ITS FLUCIDE PROGRAM, WHEN GIVEN ORALLY, LED TO STRONG ANTIVIRAL ANTIBODY RESPONSE.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Pharmaceutical Market, Chemical Company of Malaysia, Global, Major Products, 2016

REFERENCE CODE GDHC##CHR| PUBLICATION DATE SEPTEMBER 2016 HEALTHCARE, REGULATORY AND REIMBURSEMENT LANDSCAPE - MALAYSIA Executive Summary The pharmaceutical market of Malaysia has significant potential for growth.

  • Healthcare
  • Mortality
  • Pharmaceutical
  • Asia
  • Malaysia
  • Daiichi Sankyo Company Ltd - History

In May, Daiichi Sankyo Company, Limited entered into a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute for its influenza HA vaccine " Kaketsuken" .

  • Healthcare
  • Pharmaceutical
  • Japan
  • Company Financials
  • Daiichi Sankyo Company
  • PARTNERSHIPS

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Healthcare
  • Pharmaceutical
  • United States
  • Company Financials
  • AMRI
  • 9.3 BIBLIOGRAPHY

Clinical implications of antiviral resistance in influenza.

  • Clinical Trial
  • Influenza
  • Pathology
  • Therapy
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

It enables AMRI to develop and manufacture the influenza antiviral products.

  • Influenza
  • Pathology
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Healthcare
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • PARTNERSHIPS AMRI ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH BIOTA HOLDINGS FOR CS8958
  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Aviragen Therapeutics, Inc.
  • Influenza antivirals
  • Description
  • Antiviral
  • Therapy
  • Forecast
  • Market Size
  • Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Novavax, Inc.
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pathology
  • Pharmaceutical
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • PARTNERSHIP - DEAL REPORTS

a US-based contract research and manufacturing organization, has signed an agreement with Biota Holdings Limited, to further develop and manufacture Biota' s influenza antiviral CS## (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

  • Pharmaceutical
  • Respiratory Treatment
  • United States
  • Company
  • AMRI
  • RESPIRATORY SYNCYTIAL VIRUS (RSV) - OPPORTUNITY ANALYSIS AND FORECASTS TO 2024

" [Adamantane] influenza antivirals had resistance develop very quickly on therapy...

  • Epidemiology
  • Therapy
  • Vaccine
  • Ablynx NV
  • Gilead Sciences, Inc.
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Influenza
  • Pharmaceutical
  • Therapy
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • FEATURED NEWS & PRESS RELEASES

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • R&D
  • Research And Development
  • Vaccine
  • NanoViricides, Inc.
  • H1N1 Infection - Product Development Milestones

As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.

  • Influenza
  • Pharmaceutical
  • R&D
  • Research And Development
  • Vaccine
  • NAS-911 - DRUG PROFILE

In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Biotech
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes
  • PARTNERSHIP - DEAL REPORTS
  • DEAL REPORT: BIOTA SCIENTIFIC RECEIVES BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) CONTRACT
  • Pharmaceutical
  • United Kingdom
  • United States
  • Company
  • Biota Holdings Limited
  • Clinical Trial Profile Snapshots

PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE EFFECTIVENESS (EAVE) - USE OF A UNIQUE COMMUNITY AND LABORATORY NATIONAL LINKED DATASET: AN OBSERVATIONAL LONGITUDINAL COHORT STUDY WITH NESTED-CASE CONTROL STUDY EARLY ESTIMATION OF PANDEMIC INFLUENZA ANTIVIRAL AND VACCINE

  • Clinical Trial
  • Drug Discovery And Development
  • Influenza
  • Pathology
  • Vaccine
  • 10.2. DEALS BY PRECLINICAL STAGE

antiviral vaccines Collaborative R& D agreement for AVE ## safety and tolerability Licensing agreement for tkRNAi technology Grant award for Parkinson' s disease research Yes Apr 2012 BioVest, US Army Medical Research Institute of Infectious Diseases Sanofi, Michael J Fox Foundatio

  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Wildwood Ventures Limited
  • Clinical Trial Profile Snapshots

Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Prominent Drugs Pandemic Influenza Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* Pandemic Influenza Therapeutics Clinical Tr

  • Clinical Trial
  • Drug Discovery And Development
  • Influenza
  • Pathology
  • Vaccine
  • SMALL MOLECULES TO ACTIVATE SIRTUIN FOR INFLUENZA - DRUG PROFILE
  • Infectious Disease
  • Influenza
  • Pharmaceutical
  • Vaccine
  • Hemispherx Biopharma, Inc.
  • NAS-911 - DRUG PROFILE

IN JULY 2014, NEW AMSTERDAM SCIENCES (NAS) ANNOUNCED THE COMPLETION OF INITIAL CONFIRMATORY STUDIES IN ANIMAL MODELS DESIGNATING OSELTAMIVIR (TAMIFLU) AND NAS LEAD COMPOUND NAS-## AS A CO-THERAPEUTIC FOR EXISTING INFLUENZA ANTIVIRALS CURRENTLY AVAILABLE TO FLU PATIENTS.

  • Pathology
  • Pharmaceutical
  • Research And Development
  • Respiratory Disease
  • Therapy
  • H3N2 Infection - Product Development Milestones

Our agreement signifies the importance of developing new treatment options for influenza with novel mechanisms of action given the limitations of currently available influenza antivirals.

  • Influenza
  • R&D
  • Research And Development
  • Therapy
  • Vaccine
  • Drug Profiles

VH-## elicits antiviral effects.

  • Influenza
  • Pathology
  • R&D
  • Research And Development
  • Vaccine
  • H1N1 Infection - Product Development Milestones

As things stand, there are only two types of antivirals approved for treating the influenza virus (flu virus), including Tamiflu and Relenza, yet multiple strains of the flu virus are increasingly resistant to antivirals.

  • Influenza
  • Pharmaceutical
  • R&D
  • Research And Development
  • Vaccine
  • LANINAMIVIR - DRUG PROFILE

IT ENABLES AMRI TO DEVELOP AND MANUFACTURE THE INFLUENZA ANTIVIRAL PRODUCTS.

  • Cardiovascular Disease
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company
  • NAS-911 - DRUG PROFILE

In July 2014, New Amsterdam Sciences (NAS) announced the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS lead compound NAS-## as a co-therapeutic for existing influenza antivirals currently available to flu patients.

  • Biotech
  • Pathology
  • Pharmaceutical
  • Therapy
  • Type 2 Diabetes